Dr. Nicholas Botwood, MBBS

Dr. Nicholas Botwood, MBBS

Dr. Nicholas Botwood is a prominent leader and R&D visionary who has more than 25 years of experience translating scientific discoveries into novel oncology medicines and industry-leading franchises. As Head of R&D and Chief Medical Officer at Syndax Pharmaceuticals, he led the team to secure a second FDA-approved indication for Revuforj (revumenib), making it the first-ever targeted therapy approved for relapsed/refractory NPM1-mutated AML, an aggressive blood cancer associated with poor outcomes. He also spearheaded the launch of a global Phase 3 trial which incorporates a novel surrogate endpoint that could meaningfully shorten the time required to bring this promising new therapy to newly diagnosed patients with NPM1-mutated AML.

Articles by Dr. Nicholas Botwood, MBBS

Latest Updated Articles